Bauer KS - Search Results

1

Pharmacokinetics and relative bioavailability of carboxyamido-triazole with respect to food and time of administration: use of a single model for simultaneous determination of changing parameters.

Bauer KS, Kohn EC, Lush RM, Steinberg SM, Davis P, Kohler D, Reed E, Figg WD. Bauer KS, et al. J Pharmacokinet Biopharm. 1998 Dec;26(6):673-87. doi: 10.1023/a:1020750923542. J Pharmacokinet Biopharm. 1998. PMID: 10485080 Clinical Trial.

2

Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: pharmacokinetics, clinical outcome, and comparison of formulations.

Kohn EC, Figg WD, Sarosy GA, Bauer KS, Davis PA, Soltis MJ, Thompkins A, Liotta LA, Reed E. Kohn EC, et al. Among authors: bauer ks. J Clin Oncol. 1997 May;15(5):1985-93. doi: 10.1200/JCO.1997.15.5.1985. J Clin Oncol. 1997. PMID: 9164210 Clinical Trial.

3

Pharmacokinetics of cisplatin administered by continuous hyperthermic peritoneal perfusion (CHPP) to patients with peritoneal carcinomatosis.

Cho HK, Lush RM, Bartlett DL, Alexander HR, Wu PC, Libutti SK, Lee KB, Venzon DJ, Bauer KS, Reed E, Figg WD. Cho HK, et al. Among authors: bauer ks. J Clin Pharmacol. 1999 Apr;39(4):394-401. doi: 10.1177/00912709922007967. J Clin Pharmacol. 1999. PMID: 10197298 Clinical Trial.

4

A pharmacokinetically guided Phase II study of carboxyamido-triazole in androgen-independent prostate cancer.

Bauer KS, Figg WD, Hamilton JM, Jones EC, Premkumar A, Steinberg SM, Dyer V, Linehan WM, Pluda JM, Reed E. Bauer KS, et al. Clin Cancer Res. 1999 Sep;5(9):2324-9. Clin Cancer Res. 1999. PMID: 10499600 Clinical Trial.

5

A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction.

Kohn EC, Reed E, Sarosy GA, Minasian L, Bauer KS, Bostick-Bruton F, Kulpa V, Fuse E, Tompkins A, Noone M, Goldspiel B, Pluda J, Figg WD, Liotta LA. Kohn EC, et al. Among authors: bauer ks. Clin Cancer Res. 2001 Jun;7(6):1600-9. Clin Cancer Res. 2001. PMID: 11410496 Clinical Trial.

6

Clinical pharmacology of flavopiridol following a 72-hour continuous infusion.

Rudek MA, Bauer KS Jr, Lush RM 3rd, Stinson SF, Senderowicz AM, Headlee DJ, Arbuck SG, Cox MC, Murgo AJ, Sausville EA, Figg WD. Rudek MA, et al. Among authors: bauer ks jr. Ann Pharmacother. 2003 Oct;37(10):1369-74. doi: 10.1345/aph.1C404. Ann Pharmacother. 2003. PMID: 14519054 Clinical Trial.

7

Management of hormone-sensitive metastatic prostate cancer. Update on hormonal therapy.

Figg WD, Feuer JA, Bauer KS. Figg WD, et al. Among authors: bauer ks. Cancer Pract. 1997 Jul-Aug;5(4):258-63. Cancer Pract. 1997. PMID: 9250085 Review. No abstract available.

8

Pharmacokinetics of thalidomide in an elderly prostate cancer population.

Figg WD, Raje S, Bauer KS, Tompkins A, Venzon D, Bergan R, Chen A, Hamilton M, Pluda J, Reed E. Figg WD, et al. Among authors: bauer ks. J Pharm Sci. 1999 Jan;88(1):121-5. doi: 10.1021/js980172i. J Pharm Sci. 1999. PMID: 9874712 Clinical Trial.

9

Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells.

Dixon SC, Kruger EA, Bauer KS, Figg WD. Dixon SC, et al. Among authors: bauer ks. Cancer Chemother Pharmacol. 1999;43 Suppl:S78-84. doi: 10.1007/s002800051103. Cancer Chemother Pharmacol. 1999. PMID: 10357564

10

Carboxyamido-triazole inhibits angiogenesis by blocking the calcium-mediated nitric-oxide synthase-vascular endothelial growth factor pathway.

Bauer KS, Cude KJ, Dixon SC, Kruger EA, Figg WD. Bauer KS, et al. J Pharmacol Exp Ther. 2000 Jan;292(1):31-7. J Pharmacol Exp Ther. 2000. PMID: 10604929

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

39 results

Search Page

Filters